All Clinical Trials
Below is a list of all clinical trials, conducted by several of our specialty service lines. You may filter the list of trials by clicking the "Department" dropdown menu and selecting the area that you want to view or that pertains to you.
Clicking "Learn More" may either take you to more information about our departments that conduct the research, or to the official clinicaltrials.gov page for more information about the trial.
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
NRG-BN013, Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) versus Fractionated SRS (FSRS) for Intact Brain Metastases
Study # NRG-BN013 Date Opened: 12/12/2024 Closing Date: 06/30/2028 Principal Investigator: David Perry, M.D. Sponsor: NRG Oncology
A012301: LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
OptimICE-pCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (Exact 2023-05 / NSABP B-64)
Study # 2023-05 Date Opened: 09/23/2025
INTEGRATED CANCER REPOSITORY FOR CANCER RESEARCH (iCaRe2)
Head and Neck, Brain, Breast Cancer, Hematologic Cancer, GI, GU, Melanoma, Gynecologic Cancer, Lung Cancer
NRG-CC014, Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) (NCT06745024)
Study # NRG-CC014 Date Opened: 06/09/2025 Closing Date: 10/01/2028 Principal Investigator: Jason T. Shumadine, M.D. Sponsor: NRG Oncology
